Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
According to this study, over the next five years the Pemetrexed Drug market will register a xx% CAGR in terms of revenue, the global market size will reach USD xx million by 2024, from USD xx million in 2019. In particular, this report presents the global revenue market share of key companies in Pemetrexed Drug business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Pemetrexed Drug market by product type, application, key companies and key regions.
This study considers the Pemetrexed Drug value generated from the sales of the following segments-
Segmentation by product type- breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
100 mg lyophilized powder/vial
500 mg lyophilized powder/vial
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Pleural mesothelioma
Non-small cell lung cancer
This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Eli Lilly and Company
Pfizer
Teva
Eagle Pharmaceuticals
APOTEX
Qilu Pharmaceutical
Biocon
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Pemetrexed Drug market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Pemetrexed Drug market by identifying its various subsegments.
Focuses on the key global Pemetrexed Drug players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Pemetrexed Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Pemetrexed Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
